Human HPV 16 E7 Oncoprotein ELISA Kit

Name: Human HPV 16 E7 Oncoprotein ELISA Kit
SKU: DEIASL171
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Cell lysates, tissue lysates, cervical smears, plasma, serum

Species Reactivity

Human

Detection Method

sELISA

Intended Use

Human HPV16 E7 Oncoprotein ELISA Kit is an enzyme immunoassay developed for detection and quantitation of the Human Papillomavirus Type 16 E7 protein from cell lysates, tissue lysates, cervical smears, plasma and serum. Each kit provides sufficient reagents to perform up to 96 assays including standard curve and HPV16 E7 samples.

Contents of Kit

1. Anti-HPV Antibody Coated Plate: One strip well 96-well plate.
2. 100× Anti-HPV16 E7 Biotin: One 120 μL vial.
3. 100× Streptavidin-enzyme Conjugate: One 120 μL vial.
4. Recombinant HPV16 E7 Standard (500 ng): lyophilized powder.
5. Assay Diluent: One 50 mL bottle.
6. 20× Wash Buffer: One 50 mL bottle.
7. Substrate Solution: Two 6 mL bottles.
8. Stop Solution: One 7 mL bottle.

Storage

After you receive the kit, all the components should be stored in the refrigerator (4-8°C) also up to 1 year. Long term storage, improper storage conditions and large temperature fluctuation cycles may cause precipitates in the TMB solution. These precipitates should not affect the assay noticeably. Nevertheless, if you observe such precipitates, we recommend to avoid them by allowing them to sink to the bottom.

Detection Range

0.078-5ng/mL.

Sensitivity

The kit has detection sensitivity limit of 31 pg/mL HPV16 E7.

General Description

Human papillomavirus (HPV) is a large group of more than 150 related DNA viruses. HPV is named for the warts (papillomas) some types can cause and is spread through direct skin-to-skin contact. Although most HPV infections cause no symptoms and resolve spontaneously, some persist and result in warts or precancerous lesions. Of the more than 150 types, over 40 types are known to be transmitted through sexual contact and make it the most commonly sexually transmitted infection (STI).
HPV-induced cancers arise when viral sequences are integrated into the DNA of host cells. Some genes carried by the HPV virus, such as genes E6 and E7, act as oncogenes that promote tumor growth and malignant transformation. Roughly 12 HPV types (including 16, 18, 31, and 45) are classified as high-risk for being linked to malignancies. Nearly all cases of cervical cancer are associated with HPV infection, with two types present in 70% of cases: HPV16 and HPV18. Previous studies suggest that high-risk E7 oncoproteins are necessary for this cancer, by inactivating cell-cycle regulatory proteins. The ability to monitor these E7 levels may be a useful tool in cervical cancer screening and detection.

Figure 1: Schematic Presentation of the HPV Genome

Standard Curve

Citations

Have you cited DEIASL171 in a publication? Let us know and earn a reward for your research.

Background

Human papillomavirus6 (HPV-16) E7 oncoprotein is a viral protein encoded by the HPV-16 genome, which belongs to the family of human papillomaviruses. HPV-16 is one of the most common high-risk types of HPV associated with the development of cervical cancer and other HPV-related malignancies.
The E7 gene is the most important oncogene of high-risk HPV. It is in a silent phase in the early stages of HPV infection. When HPV infection persists and the HPV gene is integrated into human genes, the E7 gene is activated and a large number of oncoproteins appear. These oncoproteins are involved in various cellular protein interactions in cell cycle regulation and cell proliferation, leading to the disruption of normal cellular processes. By binding to specific host proteins, the HPV-16 E7 oncoprotein can promote cell division, inhibit cell differentiation, and override normal cell growth control mechanisms. These changes in cell behavior may lead to the development of precancerous lesions and the progression of HPV-related cancer.

Figure 1. E6 and E7 cooperatively function in the development of cervical cancer.
(Source: Narisawa-Saito, M. et al., 2007)

Detecting levels of these E7s may be a useful tool in cervical cancer screening and detection compared with traditional HPV testing. The Human HPV6 E7 Oncoprotein ELISA Kit accurately and quantitatively measures HPV-16 E7 Oncoprotein levels in samples such as tissue lysates, cell culture supernatants, or biological fluids. This allows researchers to study the expression patterns and relative abundance of HPV-16 E7 oncoproteins under different experimental conditions or clinical samples and potentially guide the development of targeted interventions.

Alternative Names

Human HPV 16 E7 Oncoprotein ELISA
Human papillomavirus6 E7 Oncoprotein ELISA
Human papillomavirus6 E7 Protein ELISA
HPV16 E7 Protein ELISA
Human papillomavirus6 E7 Oncoprotein ELISA Kit
Human papillomavirus6 E7 Protein ELISA Kit
HPV16 E7 Protein ELISA kit

References

1. Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Science. 2007, 98(10):505-1511.

Documents

pdf COA

pdf SDS

pdf Datasheet

HPV Reagents for Vaccine Research and Immunoassay Development

QA & Reviews

Customer Reviews

References

The human papillomavirus E7 oncoprotein

Virology

Authors: McLaughlin-Drubin M E, Münger K.

Abstract

The human papillomavirus (HPV) E7 oncoprotein shares functional similarities with such proteins as adenovirus E1A and SV40 large tumor antigen. As one of only two viral proteins always expressed in HPV-associated cancers, E7 plays a central role in both the viral life cycle and carcinogenic transformation. In the HPV viral life cycle, E7 disrupts the intimate association between cellular differentiation and proliferation in normal epithelium, allowing for viral replication in cells that would no longer be in the dividing population. This function is directly reflected in the transforming activities of E7, including tumor initiation and induction of genomic instability.

The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis

Cancer research and treatment: official journal of Korean Cancer Association

Authors: Yim E K, Park J S.

Abstract

Cervical cancer is one of the leading world causes of cancer morbidity and mortality in woman, with more than 98% related to a human papillomavirus (HPV) infection origin. Infection with specific subtypes of HPV has been strongly implicated in cervical carcinogenesis. The identification and functional verification of host proteins associated with HPV E6 and E7 oncoproteins may provide useful information in understanding cervical carcinogenesis and the development of cervical cancer-specific markers. The advent of functional genomics and proteomics has provided hope of discovering novel biological markers for use in the screening, early diagnosis, prognostication and prediction of response to therapy. Herein, we review the studies where the profiles of host proteins associated with HPV E6 and E7 oncoproteins in cervical cancer were generated.

Association of human papillomavirus vaccination with exposure to dental or medical visits

JOURNAL OF PUBLIC HEALTH DENTISTRY

Authors: Shukla, Anubhuti; McKenna, Maria; Hayes, Catherine; Klevens, Ruth Monina

Abstract

Background Human papillomavirus (HPV) infection is associated with oropharyngeal cancers. The Centers for Disease Control and Prevention (CDC) estimate that >15,000 new cases of HPV-associated oropharyngeal cancers are diagnosed in the United States annually. We evaluated an association between HPV vaccination and dental visits in the previous year. Methods Data were analyzed from the 2012, 2014, and 2016 Massachusetts Behavioral Risk Factor Surveillance System (MA-BRFSS) datasets. We created four categories of exposures to healthcare services in the past 12 months: a) both medical and dental visits, b) medical visit only, c) dental visit only, d) neither. Outcomes were HPV vaccination ever or influenza vaccination within the past 12 months. Logistic regression, controlled for race and education, was used to measure the association between medical/dental visits and vaccination status. Separate models were generated by sex. Results Crude and adjusted odds ratio of influenza and HPV vaccination were highest among males and females with both medical and dental visits. Women with both medical and dental provider visits had 3.7 times higher odds of being vaccinated for influenza and 1.7 times higher odds of being vaccinated for HPV. There were no differences in crude or adjusted odds among both males and females if the type of healthcare visits were only medical or only dental. Conclusion No difference in association between vaccination and medical or dental healthcare exposures suggests that oral health professionals might partner in promotion of positive health behaviors, including HPV vaccination. The type of provider did not affect the outcome as per this study.

Early Detection of Human Papillomavirus-Driven Oropharyngeal Cancer Using Serology From the Study of Prevention of Anal Cancer

JAMA ONCOLOGY

Authors: Waterboer, Tim; Brenner, Nicole; Gallagher, Richard; Hillman, Richard John; Jin, Fengyi; Grulich, Andrew; Poynten, Isobel Mary

Abstract

This case series examines HPV seropositivity and antibody levels in a cohort of older men who have sex with men.